drugset / Trial / NCT04413253
Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease
Non-randomizedCrossoverSingle-blindTreatment
Summary
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in patients with dry eye who are beginning treatment with Xiidra (lifitegrast ophthalmic solution) to reduce the signs and symptoms of dry eye disease.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2022-04-11
- Completion
- 2022-04-11
Outcome
Outcome not reported
Stopped (Enrollment): “Unable to recruit”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 0.4 mg | Other |
| Comparator | Lifitegrast | Unknown | 5 % | Other |